Newsroom | 97532 results

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that company management will participate in the following upcoming investor conferences in June: Jefferies Global Healthcare Conference on Wednesday, June 3 in New York, NY Reid Waldman, M.D., Chief Executive Officer of Veradermics, and Mark Neumann, Chief Commercial...

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 4th at 11:05 a.m. ET. A live webcast of Ironwood’s fireside chat will be accessible through the Investors & Media section of the company’s website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood’s website following the conference. About Ironwood Pharmaceutic...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that data on the long-term administration of its tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB) will be presented at the 18th International MPS & Related Lysosomal...

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the following upcoming investo...

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that Palmetto GBA has issued a final Local Coverage Determination (LCD L40205) establishing Medicare coverage guidance for irreversible electroporation (IRE), the non-thermal ablation technology delivered by the Company's NanoKnife System, in...

SEATTLE--(BUSINESS WIRE)--The Access to Advanced Health Institute (AAHI), a nonprofit biotech organization dedicated to developing vaccines and technologies for global health, today congratulates Eli Lilly and Company and Curevo Vaccine on Lilly’s acquisition of Curevo. Curevo’s lead asset, amezosvatein (CRV-101), is a Phase 3-ready subunit vaccine for the prevention of shingles (herpes zoster) that incorporates AAHI’s proprietary SLA-SE adjuvant. The acquisition underscores the growing recogni...

加州聖卡洛斯--(BUSINESS WIRE)--(美國商業資訊)-- BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235)是一家全球性腫瘤公司，今日公布HERIZON-GEA-01研究資料已刊登於The New England Journal of Medicine，並將於2026年6月1日於芝加哥舉行的美國臨床腫瘤學會(ASCO)年會上，以口頭報告（快速口頭報告：4010）形式發表。HERIZON-GEA-01臨床試驗評估ZIIHERA® (zanidatamab)聯合化療，並比較加入或不加入TEVIMBRA® (tislelizumab)的療效，對照組為trastuzumab聯合化療，用於一線治療晚期或轉移性HER2陽性胃食道腺癌。 韓國首爾延世大學醫學院延世癌症中心腫瘤內科教授，及該NEJM論文資深作者及ASCO摘要第一作者Sun Young Rha博士表示： 「HERIZON-GEA-01研究結果於The New England Journal of Medicine發表，並於ASCO口頭報告中公布，提供了關...

SAN CARLOS, California--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), empresa global de oncología, anunció hoy que los datos del estudio HERIZON-GEA-01 fueron publicados en The New England Journal of Medicine y se presentarán en una exposición oral (Rapid Oral Abstract: 4010) durante la reunión anual de la American Society of Clinical Oncology (ASCO), que se celebrará el 1 de junio de 2026 en Chicago. El ensayo clínico HERIZON-GEA-01 evaluó ZIIHERA® (zanidatamab...

SAN CARLOS, Califórnia--(BUSINESS WIRE)--A BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), empresa global de oncologia, anunciou hoje que os dados do estudo HERIZON-GEA-01 foram publicados no The New England Journal of Medicine e serão apresentados em uma sessão oral (Resumo Oral Rápido: 4010) na Reunião Anual da Sociedade Americana de Oncologia Clínica (ASCO), que ocorrerá em 1º de junho de 2026, em Chicago. O ensaio clínico HERIZON-GEA-01 avaliou a associação de ZIIHERA® (zanida...

カリフォルニア州サンカルロス--(BUSINESS WIRE)--（ビジネスワイヤ） -- BeOne Medicines Ltd.（Nasdaq：ONC、HKEX：06160、SSE：688235）は、がん領域のグローバル企業であり、HERIZON-GEA-01のデータがThe New England Journal of Medicineに掲載され、口頭発表（Rapid Oral Abstract：4010）として、シカゴで開催される米国臨床腫瘍学会（ASCO）年次総会において、2026年6月1日に発表されることを明らかにしました。HERIZON-GEA-01臨床試験では、進行／転移性HER2陽性胃食道腺がん（GEA）に対する一次治療として、ZIIHERA®（ザニダタマブ）と化学療法の併用（TEVIMBRA®（チスレリズマブ）併用および非併用）を、トラスツズマブと化学療法の併用からなる対照群と比較評価しました。 韓国・ソウルの延世大学校医科大学延世がんセンターの腫瘍内科学教授であり、NEJM論文の上席著者およびASCO抄録の筆頭著者であるSun Young Rha氏は、次のように...